THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL;CANCER RESEARCH TECHNOLOGY LIMITED
发明人:
BELLENIE, BENJAMIN RICHARD,CARTER, MICHAEL KEITH,CHEUNG, KWAI MING JACK,DAVIS, OWEN ALEXANDER,HOELDER, SWEN,LLOYD, MATTHEW GARTH,VARELA RODRIGUEZ, ANA,WOODWARD, HANNAH,INNOCENTI, PAOLO
申请号：
CA3065005
公开号：
CA3065005A1
申请日:
2018.05.25
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2 and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.
